Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

358

Enrollment

INDUSTRY

Sponsor class

Conditions

Acromegaly

Interventions

DRUG: Pasireotide
DRUG: Octreotide

Sponsor

Novartis Pharmaceuticals